Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Reckitt Benckiser LLC
ClinicalTrials.gov Identifier:
NCT01537081
First received: February 16, 2012
Last updated: October 22, 2013
Last verified: October 2013
Results First Received: July 3, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Condition: Acute Upper Respiratory Tract Infection
Interventions: Drug: Mucinex
Drug: Immediate-release Guaifenesin
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
A total of 3215 patients were screened for enrollment, and 405 did not proceed in the study. Participants were randomized in a 2:2:1 ratio.

Reporting Groups
  Description
Mucinex 2400 mg/Day The study is designed to meet regulatory requirement outside the US. The dosing regimen and assessments timepoints were dictated by IR GGE and do not match approved Mucinex labeling. Participants were instructed to take 2 Mucinex (600-mg) tablets and 1 placebo tablet matching the 200-mg IR guaifenesin tablet by mouth, every 12 hours for 7 days. To ensure complete blinding, on Hours 6 and 18, this treatment group took 2 matching Mucinex placebo tablets combined with 1 IR guaifenesin placebo tablet.
Immediate-release Guaifenesin 800 mg/Day The dosing regimen and assessments timepoints were dictated by immediate-release guaifenesin (IR GGE). Participants were instructed to take 1 immediate-release guaifenesin (IR GGE) 200 mg tablet and 2 matching Mucinex placebo tablets by mouth, every 6 hours for 7 days.
Placebo Double dummy technique was employed requiring a large number of tablets and water to be consumed. Participants were instructed to take 2 matching Mucinex placebo tablets combined with 1 matching IR guaifenesin placebo tablet by mouth, every 6 hours for 7 days.

Participant Flow:   Overall Study
    Mucinex 2400 mg/Day     Immediate-release Guaifenesin 800 mg/Day     Placebo  
STARTED     1123     1124     563  
Safety Population     1122     1122     561  
Modified Intent to Treat Population     1106     1109     556  
COMPLETED     1084     1086     547  
NOT COMPLETED     39     38     16  
Adverse Event                 5                 2                 2  
Lack of Efficacy                 2                 1                 0  
Lost to Follow-up                 17                 15                 9  
Protocol Violation                 3                 2                 2  
Withdrawal by Subject                 6                 11                 3  
Physician Decision                 5                 6                 0  
Sponsor decision                 0                 1                 0  
Assigned but never dosed                 1                 0                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Based on the Safety population, defined as all patients who received at least one dose of the study medication, excluding patients who later return all the dispensed study medication to the site unused.

Reporting Groups
  Description
Mucinex 2400 mg/Day The study is designed to meet regulatory requirement outside the US. The dosing regimen and assessments timepoints were dictated by IR GGE and do not match approved Mucinex labeling. Participants were instructed to take 2 Mucinex 600-mg tablets and 1 placebo tablet matching the 200 mg IR guaifenesin tablet by mouth, every 12 hours for 7 days. To ensure complete blinding, on Hours 6 and 18, this treatment group took 2 matching Mucinex placebo tablets combined with 1 IR guaifenesin placebo tablet.
Immediate-release Guaifenesin 800 mg/Day The dosing regimen and assessments timepoints were dictated by immediate-release guaifenesin (IR GGE). Participants were instructed to take 1 immediate-release guaifenesin (IR GGE) 200 mg tablet and 2 matching Mucinex placebo tablets by mouth, every 6 hours for 7 days.
Placebo Double dummy technique was employed requiring a large number of tablets and water to be consumed. Participants were instructed to take 2 matching Mucinex placebo tablets combined with 1 matching IR guaifenesin placebo tablet by mouth, every 6 hours for 7 days.
Total Total of all reporting groups

Baseline Measures
    Mucinex 2400 mg/Day     Immediate-release Guaifenesin 800 mg/Day     Placebo     Total  
Number of Participants  
[units: participants]
  1122     1122     561     2805  
Age  
[units: years]
Mean ± Standard Deviation
  37.3  ± 13.81     36.8  ± 13.81     37.9  ± 14.09     37.2  ± 13.87  
Gender  
[units: participants]
       
Female     670     668     333     1671  
Male     452     454     228     1134  
Race/Ethnicity, Customized  
[units: participants]
       
American Indian or Alaska Native     1     7     2     10  
Asian     31     25     13     69  
Native Hawaiian or Other Pacific Islander     4     3     3     10  
Black or African American     382     419     200     1001  
White     686     656     327     1669  
Other     18     12     16     46  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Summary Scores on the SUM8 Daily Cough and Phlegm Diary Card On the Morning of Day 4   [ Time Frame: Day 4 ]

2.  Primary:   Summary Scores on the SUM8 Daily Cough and Phlegm Diary Card On the Morning of Day 5   [ Time Frame: Day 5 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Gail Solomon,MS; Director Clinical Development
Organization: Reckitt Benckiser LLC
phone: 973-404-2752
e-mail: gail.solomon@rb.com


No publications provided


Responsible Party: Reckitt Benckiser LLC
ClinicalTrials.gov Identifier: NCT01537081     History of Changes
Other Study ID Numbers: 2011-MUC-04
Study First Received: February 16, 2012
Results First Received: July 3, 2013
Last Updated: October 22, 2013
Health Authority: United States: Food and Drug Administration